
Quarterly report 2022-Q4
added 11-07-2022
Allscripts Healthcare Solutions Financial Statements 2011-2025 | MDRX
Annual Financial Statements Allscripts Healthcare Solutions
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.34 B | 2.66 B | 1.49 B | 2.06 B | 2.73 B | 2.14 B | 2.55 B | 2.14 B | 2.95 B | 2.01 B | 3.56 B |
Shares |
130 M | 161 M | 166 M | 176 M | 181 M | 186 M | 185 M | 180 M | 177 M | 179 M | 189 M |
Historical Prices |
18.4 | 14.4 | 9.82 | 9.64 | 14.6 | 10.2 | 15.4 | 12.8 | 15.5 | 9.42 | 18.9 |
Net Income |
134 M | 700 M | -182 M | 364 M | -196 M | -25.7 M | -2.23 M | -66.5 M | -104 M | -1.15 M | 73.6 M |
Revenue |
1.5 B | 1.5 B | 1.77 B | 1.75 B | 1.81 B | 1.55 B | 1.39 B | 1.38 B | 1.37 B | 1.45 B | 1.44 B |
Cost of Revenue |
883 M | 937 M | 1.02 B | 996 M | 865 M | 785 M | 806 M | 832 M | 839 M | 840 M | 28.1 M |
Gross Profit |
620 M | 566 M | 714 M | 725 M | 782 M | 671 M | 581 M | 546 M | 534 M | 607 M | 666 M |
Operating Income |
77.2 M | -131 M | -99.7 M | -168 M | 12.5 M | 67.7 M | 31.9 M | -39.2 M | -128 M | 13.3 M | 137 M |
Interest Expense |
13.2 M | 34.1 M | 43.2 M | 50.9 M | 37.5 M | 29.5 M | 31.4 M | 29.3 M | 28.1 M | 16.2 M | 20.8 M |
EBITDA |
253 M | -30.3 M | 39.3 M | 5.17 M | 75.7 M | 90.3 M | 56.6 M | -5.52 M | -84.9 M | 60 M | 174 M |
Operating Expenses |
- | 622 M | 701 M | 746 M | 740 M | 607 M | 547 M | 583 M | 651 M | 582 M | 529 M |
General and Administrative Expenses |
314 M | 390 M | 420 M | 451 M | 486 M | 393 M | 339 M | 359 M | 420 M | 384 M | 388 M |
All numbers in USD currency
Quarterly Income Statement Allscripts Healthcare Solutions
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 110 M | 114 M | 116 M | 116 M | 124 M | 137 M | 140 M | 140 M | 161 M | 163 M | 162 M | 162 M | 166 M | 167 M | 170 M | 171 M | 175 M | 176 M | 180 M | 181 M | 181 M | 181 M | 181 M | 181 M | 186 M | 187 M | 189 M | 189 M | 189 M | 182 M | 181 M | 180 M | 180 M | 180 M | 179 M | 179 M | 178 M | 178 M | 174 M | 172 M | 171 M | 182 M | 191 M | 190 M | 188 M | 190 M | 189 K |
Net Income |
- | 14.5 M | -64 M | 22.9 M | - | 16.2 M | 21.9 M | 9.06 M | 728 M | 542 K | -7.6 M | -20.4 M | -19 M | -5.72 M | -150 M | -7.98 M | 386 M | -23.8 M | 74.3 M | -28.5 M | 14.9 M | -17.5 M | -143 M | -20 M | -7.31 M | -10.2 M | -10.2 M | 2.05 M | 16.3 M | -5.24 M | -3.22 M | -10.1 M | -2.18 M | -25.8 M | -17.8 M | -20.7 M | -20.6 M | -48.9 M | -22.9 M | -11.6 M | - | 9.38 M | 7.98 M | 5.81 M | - | 19.1 M | 15.9 M | 12.6 M |
Revenue |
- | 152 M | 151 M | 143 M | 392 M | 145 M | 141 M | 134 M | 386 M | 366 M | 369 M | 381 M | 414 M | 408 M | 411 M | 399 M | 442 M | 432 M | 526 M | 514 M | 517 M | 449 M | 426 M | 413 M | 425 M | 392 M | 387 M | 346 M | 346 M | 354 M | 352 M | 335 M | 341 M | 345 M | 351 M | 340 M | 351 M | 330 M | 345 M | 347 M | - | 361 M | 370 M | 365 M | - | 364 M | 357 M | 335 M |
Cost of Revenue |
- | 68.5 M | 71.4 M | 69.2 M | - | 75 M | 72.8 M | 70.7 M | 225 M | 230 M | 232 M | 249 M | 262 M | 260 M | 252 M | 249 M | 254 M | 254 M | 268 M | 249 M | 260 M | 206 M | 200 M | 199 M | 239 M | 226 M | 220 M | 194 M | 192 M | 201 M | 208 M | 205 M | 205 M | 214 M | 211 M | 202 M | 213 M | 205 M | 209 M | 213 M | - | 204 M | 212 M | 209 M | - | 10 M | 5 M | 175 M |
Gross Profit |
- | 83.4 M | 79.5 M | 73.5 M | - | 69.6 M | 68.4 M | 62.9 M | 161 M | 135 M | 138 M | 132 M | 153 M | 149 M | 159 M | 150 M | 188 M | 178 M | 174 M | 185 M | 176 M | 162 M | 150 M | 144 M | 186 M | 166 M | 167 M | 152 M | 154 M | 153 M | 144 M | 130 M | 136 M | 131 M | 140 M | 138 M | 138 M | 126 M | 136 M | 134 M | - | 157 M | 157 M | 156 M | - | 162 M | 168 M | 160 M |
Operating Income |
- | 25 M | -5.36 M | 6.57 M | - | 18.5 M | 16.8 M | 7.73 M | -68.1 M | -11.2 M | -24.7 M | -27 M | -55.1 M | -15.7 M | -13.6 M | -15.3 M | -26.4 M | 186 K | -60.1 M | -6.7 M | -21.3 M | 18.2 M | 13.2 M | 2.35 M | 12.4 M | 16.9 M | 18.6 M | 11.9 M | 23.1 M | 8.87 M | 5.59 M | -5.7 M | 656 K | -18.8 M | -9.09 M | -11.9 M | -27.5 M | -43.5 M | -28.3 M | -28.3 M | - | 9.18 M | 17.7 M | 13 M | - | 34.4 M | 32.1 M | 24.5 M |
Interest Expense |
- | 1.25 M | 1.89 M | 2.14 M | - | 3.62 M | 2.95 M | 3.14 M | 6.46 M | 6.67 M | 10.3 M | 10.7 M | 11.7 M | 10.8 M | 10.4 M | 10.2 M | 14 M | 13.3 M | 12 M | 11.7 M | 11.6 M | 9.25 M | 8.28 M | 8.42 M | 25.4 M | 19.4 M | 16.4 M | 6.97 M | -98 K | 423 K | -28 K | 7.26 M | 7.29 M | 7.54 M | 7.23 M | 7.23 M | 7.02 M | 6.9 M | 9.5 M | 4.64 M | - | 3.72 M | 4.36 M | 3.85 M | - | 3.75 M | 5.05 M | 7.93 M |
EBITDA |
- | 67.3 M | 23.1 M | 20.7 M | - | 67.5 M | 49.8 M | 24 M | -68.1 M | 135 M | 74.6 M | 22.5 M | -55.1 M | 137 M | 87 M | 34.9 M | -19.5 M | 143 M | 35.1 M | 41.2 M | -15.3 M | 173 M | 115 M | 52 M | 23.3 M | 137 M | 95.2 M | 46.3 M | 27.3 M | 133 M | 89.1 M | 36 M | 9.52 M | 113 M | 79.6 M | 33.2 M | -19.9 M | 88.3 M | 56.6 M | 13.7 M | - | 120 M | 90.6 M | 48.2 M | - | 132 M | 95.8 M | 55.3 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 352 M | - | - | - | 311 M |
General and Administrative Expenses |
- | 32.5 M | 59.8 M | 41.3 M | - | 27.4 M | 28.1 M | 32.2 M | 93.8 M | 93.4 M | 110 M | 92.8 M | 108 M | 96.1 M | 100 M | 96 M | 100 M | 108 M | 123 M | 120 M | 123 M | 93.8 M | 91 M | 92.8 M | 115 M | 98.8 M | 94.8 M | 84.2 M | 79.4 M | 91 M | 86.7 M | 82 M | 85 M | 97 M | 86.7 M | 89.9 M | 109 M | 105 M | 102 M | 104 M | - | 90.4 M | 92.3 M | 97.3 M | - | 92.2 M | 102 M | 104 M |
All numbers in USD currency
Main types of financial statements Allscripts Healthcare Solutions MDRXFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Allscripts Healthcare Solutions plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Health information services industry
Issuer | Price | % 24h | Market Cap | Country | |
---|---|---|---|---|---|
![]() |
Computer Programs and Systems
CPSI
|
$ 9.25 | 4.4 % | $ 133 M | ![]() |
![]() |
HealthStream
HSTM
|
$ 27.18 | 1.08 % | $ 826 M | ![]() |
![]() |
Covetrus
CVET
|
$ 20.99 | - | $ 2.94 B | ![]() |
![]() |
NantHealth
NH
|
$ 1.35 | -46.64 % | $ 10.4 M | ![]() |
![]() |
Cerner Corporation
CERN
|
$ 94.92 | - | $ 27.9 B | ![]() |
![]() |
Castlight Health, Inc.
CSLT
|
$ 1.4 | -7.28 % | $ 227 M | - |
![]() |
Change Healthcare
CHNG
|
$ 27.49 | - | $ 9.03 B | ![]() |
![]() |
HMS Holdings Corp.
HMSY
|
$ 36.975 | - | $ 3.29 B | ![]() |
![]() |
Inovalon Holdings, Inc.
INOV
|
$ 41.06 | - | $ 6.37 B | ![]() |
![]() |
R1 RCM
RCM
|
$ 14.31 | - | $ 3.81 B | ![]() |
![]() |
1Life Healthcare
ONEM
|
$ 16.47 | - | $ 3.37 B | ![]() |
![]() |
Signify Health
SGFY
|
$ 30.49 | -0.02 % | $ 7.21 B | - |
![]() |
10x Genomics
TXG
|
$ 12.07 | 4.05 % | $ 1.41 B | ![]() |
![]() |
NextGen Healthcare
NXGN
|
$ 23.94 | - | $ 1.6 B | ![]() |
![]() |
Tabula Rasa HealthCare
TRHC
|
$ 10.5 | - | $ 255 M | ![]() |
![]() |
Zhongchao
ZCMD
|
$ 1.17 | -2.51 % | $ 6.09 M | ![]() |
![]() |
MTBC
MTBC
|
$ 3.43 | -0.58 % | $ 51.7 M | ![]() |
![]() |
GoodRx Holdings
GDRX
|
$ 4.39 | - | $ 1.69 B | ![]() |
![]() |
HealthEquity
HQY
|
$ 92.09 | 4.06 % | $ 7.88 B | ![]() |
![]() |
Health Catalyst
HCAT
|
$ 2.85 | - | $ 172 M | ![]() |
![]() |
Progyny
PGNY
|
$ 20.58 | 2.9 % | $ 1.77 B | ![]() |
![]() |
iCAD
ICAD
|
$ 3.87 | - | $ 102 M | ![]() |
![]() |
American Well Corporation
AMWL
|
$ 6.26 | 3.64 % | $ 93.9 M | ![]() |
![]() |
Evolent Health
EVH
|
$ 8.05 | -0.8 % | $ 754 M | ![]() |
![]() |
Omnicell
OMCL
|
$ 31.45 | 3.97 % | $ 1.45 B | ![]() |
![]() |
SCWorx Corp.
WORX
|
$ 0.31 | 0.66 % | $ 452 K | ![]() |
![]() |
Akerna Corp.
KERN
|
$ 6.27 | - | $ 161 M | ![]() |
![]() |
OptimizeRx Corporation
OPRX
|
$ 18.24 | 1.62 % | $ 312 M | ![]() |
![]() |
Phreesia
PHR
|
$ 23.25 | -0.68 % | $ 1.27 B | ![]() |
![]() |
Premier
PINC
|
$ 28.21 | 1.07 % | $ 2.32 B | ![]() |
![]() |
Accolade
ACCD
|
$ 7.03 | 0.29 % | $ 206 M | ![]() |
![]() |
Streamline Health Solutions
STRM
|
$ 5.33 | - | $ 21.4 M | ![]() |
![]() |
Teladoc Health
TDOC
|
$ 9.09 | 8.6 % | $ 1.55 B | ![]() |
![]() |
Schrödinger
SDGR
|
$ 20.72 | 2.78 % | $ 1.51 B | ![]() |
![]() |
Veeva Systems
VEEV
|
$ 301.8 | -1.44 % | $ 48.4 B | - |
![]() |
So-Young International
SY
|
$ 3.81 | 0.26 % | $ 302 M | ![]() |